Balyasny Asset Management LLC Mannkind Corp Transaction History

Balyasny Asset Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$3.34 - $4.29 $455,903 - $585,576	136,498 New	136,498 $496,000
Q2 2023 Aug 14, 2023	BUY	$3.72 - $4.79 $538,406 - $693,271	144,733 Added 195.58%	218,735 $890,000
Q1 2023 May 15, 2023	BUY	$3.95 - $5.63 $292,307 - $416,631	74,002 New	74,002 $303,000
Q3 2022 Nov 14, 2022	BUY	$2.99 - $4.35 $303,996 - $442,268	101,671 New	101,671 $314,000
Q2 2022 Aug 15, 2022	SELL	$2.67 - $4.77 $27,573 - $49,259	-10,327 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$2.62 - $4.45 $27,056 - $45,955	10,327 New	10,327 $38,000
Q4 2017 Feb 14, 2018	SELL	$2.28 - $6.71 $1.41 Million - $4.16 Million	-619,800 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$1.15 - $2.29 $712,770 - $1.42 Million	619,800	619,800 $1.35 Million

244

148M

1.62M

802K

Ticker MNKD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 257,338,000
Market Cap $1.57B
Description
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.